NCT04651127 2026-03-10
Anti-PD-1 Antibody Combined With Histone Deacetylase Inhibitor in Patients With Advanced Cervical Cancer
Sun Yat-sen University
Phase 1/2 Terminated
Clinical Trials
23 trialsNCT07412262 2026-02-17
A Prospective, Single-Arm, Multicenter, Phase II Clinical Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer With Acquired Resistance to Immunotherapy and High YAP Protein Expression
Guangdong Association of Clinical Trials
Phase 2 Not yet recruiting
NCT07397832 2026-02-09
CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting
NCT06951997 2026-01-26
QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting
NCT07339527 2026-01-14
EZH2 Inhibitor Zeprumetostat in Combination Therapy for Patients With Relapsed or Refractory Mature T-cell and NK-cell Lymphomas
Sun Yat-sen University
Phase 1/2 Not yet recruiting
NCT06776952 2026-01-09
A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
Evopoint Biosciences Inc.
Phase 3 Recruiting
NCT07093710 2025-12-31
Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma
Sun Yat-sen University
Phase 1/2 Recruiting
NCT07304232 2025-12-26
CM-AML-001
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Recruiting
NCT05141357 2025-12-24
HBI-8000
HUYABIO International, LLC.
Phase 2 Terminated
NCT05991973 2025-12-05
Low-dose Chidamide Maintenance Therapy After Allo-HSCT for T-cell Acute Lymphoblastic Leukemia or T-cell Lymphomas
Zhejiang University
Phase 2 Completed
NCT06421948 2025-12-05
Linperlisib Combined With Chidamide in Patients With PTCL
Henan Cancer Hospital
Phase 1/2 Recruiting
NCT05566054 2025-11-21
Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia
The First Affiliated Hospital of Soochow University
Phase 2 Recruiting
NCT07234162 2025-11-18
A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)
Dizal Pharmaceuticals
Phase 3 Recruiting
NCT06451861 2025-11-17
Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML
Guangdong Provincial People's Hospital
Phase 2 Recruiting
NCT05270200 2025-09-25
Single Arm Study of Post-transplant Azacitidine and Chidamide for Prevention of Acute Myelogenous Leukemia Relapse
Zhujiang Hospital
Phase 1/2 Recruiting
NCT06947967 2025-09-15
Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype
Chipscreen Biosciences, Ltd.
Phase 3 Recruiting
NCT07159620 2025-09-08
Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients
The First Affiliated Hospital of Soochow University
Phase 2 Recruiting
NCT07133776 2025-08-21
Application of PD-1 Inhibitors Combined With Tenofovir, Chidamide and Lenalidomide in the Treatment of EBV-associated Diseases.
The Affiliated Hospital of Xuzhou Medical University
Phase 1/2 Not yet recruiting
NCT06556862 2025-08-13
Exploration of Dalpiciclib Plus HDACi in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor
Beijing 302 Hospital
Phase 2 Not yet recruiting
NCT07081607 2025-07-23
Golidocitinib With Azacitidine and Chidamide in Patients With Peripheral T-cell Lymphoma.
Ruijin Hospital
Phase 2 Not yet recruiting
NCT05632848 2025-07-21
Chidamide Combined With Zimberelimab in the Treatment of Metastatic Triple-negative Breast Cancer Patients
Sun Yat-sen University
Phase 2 Completed
NCT04668690 2025-05-31
Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 3 Active not recruiting
NCT06930118 2025-04-16
The Aim of This Study is to Assess the Efficacy and Safety of Chidamide, Regorafenib in Combination With Iparomlimab and Tuvonralimab for the Treatment of Advanced Colorectal Cancer in Third-line Therapy and Subsequent Lines.
Shanghai Changzheng Hospital
Phase 2 Recruiting